Physician profile
Dharmesh N Sheth
NPI 1265493555
$13,545.24
in general payments reported to CMS, 2019-2025
30 companies · $15.92 in 2025
The $15.92 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,063 · 2020: $877 · 2021: $355 · 2022: $2,843 · 2023: $3,906 · 2024: $2,485 · 2025: $15.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,280 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,279.57 |
| Education | $127.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,699.19 | 2021-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,188.00 | 2019-2024 | Uzedy, Austedo, Austedo Xr |
| Alkermes, INC. | $1,077.43 | 2019-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $968.71 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $947.63 | 2022-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $921.59 | 2019-2024 | Spravato, Invega Trinza, Invega Sustenna |
| Neurocrine Biosciences, INC. | $872.71 | 2019-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $750.91 | 2019-2024 | Hetlioz, Fanapt |
| Sunovion Pharmaceuticals INC. | $697.35 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $642.36 | 2019-2024 | Jornay Pm |
| Lundbeck LLC | $565.25 | 2019-2024 | Rexulti |
| Allergan, INC. | $528.49 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $463.23 | 2021-2024 | Qelbree, Qelbree |
| Corium, LLC | $432.30 | 2022-2024 | Azstarys |
| Axsome Therapeutics, INC. | $316.23 | 2023-2024 | Auvelity |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $278.16 | 2019-2023 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $242.62 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $166.01 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Bausch Health US, LLC | $125.76 | 2019-2024 | Aplenzin |
| Neos Therapeutics, LP | $121.27 | 2019-2020 | |
| Indivior INC. | $113.48 | 2019-2023 | Perseris |
| Tris Pharma INC | $112.14 | 2023-2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $69.25 | 2022-2024 | Quviviq |
| Neuronetics, INC. | $62.26 | 2022-2024 | Neurostar Tms Therapy System |
| Adlon Therapeutics L.P. | $55.80 | 2019-2020 | |
| Noven Therapeutics, LLC | $39.73 | 2023 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $30.29 | 2019-2024 | Relexxii |
| Avanir Pharmaceuticals, INC. | $23.84 | 2019 | |
| Sage Therapeutics, LLC | $17.30 | 2023 | |
| Arbor Pharmaceuticals, INC. | $15.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dharmesh Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.